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Sir,
In the treatment of cutaneous T-cell lymphomas, radio-
therapy plays a well-known role in the management of
mycosis fungoides (MF) and Se´zary syndrome, as
localized radiotherapy or total skin electron-beam
irradiation. Furthermore, radiotherapy has been indi-
cated as first choice treatment in large cell CD30+
lymphomas (LCCD30+L) (1, 2), and in pleomorphic
small/medium-sized cells lymphomas (PSMSL) (1, 3, 4).
The former is characterized by a single nodular-
ulcerative lesion or grouped nodules, rarely multifocal,
sometimes spontaneously regressing, showing histo-
pathologically a diffuse non-epidermotropic infiltrate
of large cells expressing CD30 phenotype. The latter is
defined by the occurrence of one or several dark red
nodules, due to a neoplastic infiltrate of pleomorphic
small/medium-sized cells, without clinical evidence of
concurrent patches typical for mycosis fungoides. In
this short report we update our data on the radi-
ological treatment of LCCD30+L (5), evaluate the
results of radiotherapy in the treatment of PSMSL,
and compare our findings with those reported in the
literature (1–4, 6).
PATIENTS AND METHODS
In the period 1990–2003, a total of 186 new patients diagnosed
with primary cutaneous lymphomas were referred to our
department for radiotherapy. Eighteen (9.7%) had a diagnosis
of LCCD30+L and 8 (4.3%) of PSMSL (Table I). Before
treatment, all patients underwent histopathological investiga-
tion with immunophenotyping of the lymphoid infiltrate (1).
The molecular biology investigations were performed in
only four patients from each group and were positive for
monoclonal re-arrangement in three patients affected by
LCCD30+L and two patients with PSMSL. In all patients
complete staging procedures ruled out the presence of
extracutaneous localization of the disease. The diagnosis
of primary cutaneous disease was mandatory for the selection
of clinical cases to be treated by radiotherapy only.
Radiotherapy was administered as the sole treatment in all
cases, except in one case of LCCD30+L, who received s.c.
interferon-a 3 million IU every second day.
The radiological treatment was conducted by conventional
techniques. Forty-three fields of irradiation were performed
with total doses ranging from 15 to 30 Gy for LCCD30+L
(median 20 Gy) and from 20 to 30 Gy for PSMSL (median
30 Gy). The irradiation field encompassed a 1–1.5 cm margin
of healthy skin around the lesion.
RESULTS
The total follow-up ranged from 1 to 148 months (mean
48 months) for LCCD30+L and from 6 to 91 months
(mean 31.9 months) for PSMSL. All treated lesions in
both groups achieved complete remission as evaluated at
the first follow-up with a 5-year relapse-free rate of
49.84% for LCCD30+L and of 80% for PSMSL,
calculated according to the actuarial method of
survival tables (7). After complete remission of the
treated lesion, one patient with LCCD30+L underwent
adjuvant chemotherapy under the surveillance of
haematologists, as the initial clinical appearance of the
cutaneous disease was aggressive, but with no evidence
of other localizations.
In the LCCD30+L group no relapses were observed
in the irradiation fields, while we noticed skin
relapses in the same anatomical area as the primary
lesion in three cases; skin relapse in different anato-
mical areas occurred in three cases. Three patients
developed lymph node involvement; in one case it
was associated with a cutaneous relapse far from
the primary lesion. In the PSMSL group, marginal
recurrence was observed in one case; in another case
two new nodules occurred in the same area as the
primary lesion.
Up to now no acute or chronic complications of
radiotherapy have been observed.
Table I. Clinical features and localization of tumours in the
CD30+ lymphomas (LCCD30+L) and pleomorphic small/
medium-sized cells lymphoma (PSMSL) groups
Parameter LCCD30+L PSMSL
No. of patients 18 10
Age 12–83 years 29–78 years
Sex, women/men 7/11 7/3
No. of lesions 33 11
nodular 15 6
nodular-ulcerative 10 –
plaque 8 5
Localization
limbs 17 1
trunk 11 6
face 3 4
other 2 0
Total follow-up 1–148 months 6–91 months
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DISCUSSION
The evaluation of the role of radiotherapy in treating
primary cutaneous T-cell lymphomas without MF skin
lesions needs selected cases based on accurate staging
(8). The two groups of patients presented were
diagnosed as LCCD30+L and PSMSL, respectively.
While the first is defined as a disease with indolent
clinical behaviour (2, 8), the second is classified among
the ‘provisional’ entities (1). Our series of patients are
not large, but allow us to highlight some points. In the
LCCD30+L group the initial response to radiotherapy
was good after administration of a median total dose of
20 Gy: all lesions responded quickly to radiotherapy,
going into complete remission. The 5-year relapse-free
rate was 49.8%. Skin relapses never occurred in the
irradiation field, but were observed in new skin
localizations, which were treated successfully by a new
course of radiotherapy or with systemic treatment. In
two patients who developed lymph node involvement,
salvage therapies (electron-beam and/or chemotherapy)
brought the disease into remission, while a third case
was lost to follow-up. Therefore, radiotherapy was
curative in half of the patients and useful in the
treatment of the recurrence of the disease, when
confined to the skin. However, with the onset of new
multiple skin lesions, radiotherapy was combined with
systemic treatments.
The small series of PSMSL patients showed an
excellent response to radiotherapy with a median total
dose of 30 Gy. The 5-year relapse-free rate was 80%.
The two patients who relapsed have been re-treated and
do not show extracutaneous disease progression. Such
observations should indicate a good prognosis, when the
disease is presenting as single or a few lesions (4). In
these cases radiotherapy is a treatment of choice, being a
local and selective treatment modality.
Finally, our findings support the effectiveness of
radiotherapy as also reported in the literature (1–6, 8).
Its major role relates to treatment of single or few
lesions as an alternative to surgical excision. Our
experience is based on the use of conventional radio-
therapy techniques (50–120 kV). The results appear
similar to those obtained with high energies (9), and
confirm the value of the skin diseases-dedicated
machines (10), especially in situations where high-tech
devices are not available. The treatment has been well
tolerated and devoid of noticeable side effects because of
a relatively low dose of irradiation.
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